* Annovis Bio Inc reported a quarterly adjusted loss of 97 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.63. The mean expectation of six analysts for the quarter was for a loss of 53 cents per share. Wall Street expected results to range from -65 cents to -38 cents per share.
* Reported revenue was zero; analysts expected zero.
* Annovis Bio Inc's reported EPS for the quarter was a loss of 97 cents.
* The company reported a quarterly loss of $12.64 million.
* Annovis Bio Inc shares had risen by 6.8% this quarter and lost 54.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 49.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Annovis Bio Inc is $26.00 This summary was machine generated from LSEG data November 9 at 12:25 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.53 -0.97 Missed
Jun. 30 2024 -0.63 -0.32 Beat
Mar. 31 2024 -0.80 -0.10 Beat
Dec. 31 2023 -1.30 -2.24 Missed
Comments